Phase 1
Completed N=54
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
Healthy
Source: ClinicalTrials.gov NCT04050670 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcomePrimary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞]) — 112000; 111000; 106000 Hour * nanogram per milliliter (h*ng/mL)
Summary
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞]) |
112000; 111000; 106000 | — |
| PRIMARY PK: Maximum Concentration (Cmax) of Tirzepatide |
603; 556; 520 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures
- Are between the body mass index (BMI) of 18.5 and 45.0 kilograms per meter squared (kg/m²), inclusive, at screening
- Are agreeable to receiving study treatment by injections under the skin
Exclusion Criteria
- Have known allergies to tirzepatide or related compounds
- Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
- Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
- Have a prior history of malignant disease(s) in the past 5 years prior to screening
- Smoke more than the equivalent of 10 cigarettes per day
- Is a known user of drugs of abuse
Data sourced from ClinicalTrials.gov (NCT04050670). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.